Copyright
©The Author(s) 2019.
World J Clin Cases. Sep 6, 2019; 7(17): 2450-2462
Published online Sep 6, 2019. doi: 10.12998/wjcc.v7.i17.2450
Published online Sep 6, 2019. doi: 10.12998/wjcc.v7.i17.2450
Table 1 Demographic characteristics of the patients
Characteristics | Groups | P value | ||
A | B | |||
n | 486 | 289 | 197 | 0.614 |
Gender | Male | 148 | 108 | 0.715 |
Female | 141 | 89 | ||
Age in yr | 36.25 ± 15.43 | 35.20 ± 14.14 | 0.710 | |
Etiology | Hepatitis B | 184 | 131 | 0.743 |
Hepatitis C | 51 | 32 | ||
Ethanol consumption | 34 | 26 | ||
Cryptogenic hepatitis | 10 | 8 | ||
Child-Pugh score | A | 37 | 21 | 0.584 |
B | 213 | 153 | ||
C | 35 | 27 | ||
Model for end-stage liver disease score | 9.49 ± 2.05 | 9.35 ± 1.99 | 0.508 | |
Variceal bleeding | 365 | 215 | 150 | 0.329 |
Refractory ascites | 121 | 76 | 45 | 0.672 |
Both variceal bleeding and refractory ascites | 86 | 52 | 34 | 0.481 |
Laboratory tests | ||||
Alanine transaminase as U/L | 59.34 ± 11.41 | 63.05 ± 10.17 | 0.742 | |
Aspartate transaminase as U/L | 72.36 ± 12.09 | 68.45 ± 13.23 | 0.689 | |
Alkaline phosphatase as U/L | 193.43 ± 24.62 | 208.49 ± 32.54 | 0.893 | |
Total bilirubin as μmol/L | 14.03 ± 5.15 | 16.21 ± 4.28 | 0.754 | |
Albumin as g/L | 31.29 ± 1.46 | 29.19 ± 1.48 | 0.431 | |
Prothrombin time in s | 14.72 ± 3.28 | 15.43 ± 3.17 | 0.638 | |
Platelet count as × 109/L | 45.27 ± 12.38 | 38.39 ± 13.47 | 0.374 | |
Clinical presentation | ||||
Abdominal distention | 146 | 85 | 0.243 | |
Abdominal pain | 78 | 49 | 0.217 | |
Weakness | 46 | 37 | 0.158 | |
Poor appetite | 163 | 117 | 0.362 | |
Jaundice | 42 | 29 | 0.293 | |
Lower limbs edema | 32 | 24 | 0.675 | |
Endoscopic therapy | 538 | 372 | 0.427 | |
Ascites paracentesis | 227 | 147 | 0.489 |
Table 2 Clinical characteristics of the patients
Characteristics | Group | n | Portal vein thrombosis | Portal vein thrombo-sis rate | χ2 | P va-lue | ||||
Yes | No | |||||||||
Portal vein thrombosis | A | 289 | 65 | 224 | 11.0 | 25.60 | 0.003 | |||
B | 197 | 87 | 110 | 44.2 | ||||||
TIPS success | TIPS success rate (%) | |||||||||
Yes | Not | |||||||||
TIPS | A | 289 | 255 | 34 | 88.2 | 19.28 | 0.016 | |||
B | 197 | 144 | 53 | 73.1 | ||||||
Portosystemic gradient (mmHg) Pre-TIPS | A | 255 | 32.43 ± 6.64 | 0.447 | ||||||
B | 144 | 31.90 ± 4.63 | ||||||||
Portosystemic gradient (mmHg) Post-TIPS | A | 255 | 11.15 ± 1.20 | 0.027 | 0.605 | |||||
0.025 |
Table 3 Clinical characteristics of the patients in stent primary patency rate
Time | Group | Patency | Patency rate, % | χ2 | P value | |||
Yes | Not | |||||||
3 mo | A | 249 | 6 | 97.6 | 15.18 | 0.006 | ||
B | 127 | 17 | 88.1 | |||||
6 mo | A | 226 | 29 | 88.6 | 10.34 | 0.011 | ||
B | 109 | 35 | 75.7 | |||||
9 mo | A | 215 | 40 | 84.3 | 14.24 | 0.023 | ||
B | 98 | 46 | 68.1 | |||||
12 mo | A | 177 | 78 | 69.4 | 25.93 | 0.032 | ||
B | 65 | 79 | 45.1 | |||||
2 yr | A | 130 | 125 | 51.0 | 22.75 | 0.037 | ||
B | 38 | 106 | 26.4 | |||||
3 yr | A | 78 | 177 | 30.6 | 21.39 | 0.028 | ||
B | 18 | 126 | 12.5 | |||||
Median stent patency in mo | Four quantile spacing in mo | |||||||
Total | A | 12 | (10, 14) | 0.001 |
Table 4 Clinical characteristics of the patients in recurrent bleeding rate
Time | Group | Bleeding | Recurrence of bleeding, % | χ2 | P value | |
Yes | No | |||||
3 mo | A | 13 | 242 | 5.1 | 12.13 | ≤ 0.001 |
B | 21 | 123 | 14.6 | |||
6 mo | A | 25 | 230 | 9.8 | 19.53 | 0.003 |
B | 37 | 107 | 25.7 | |||
9 mo | A | 39 | 216 | 15.3 | 13.18 | 0.005 |
B | 43 | 101 | 29.8 | |||
12 mo | A | 51 | 204 | 20.0 | 20.90 | 0.008 |
B | 57 | 87 | 39.6 | |||
2 yr | A | 74 | 181 | 29.0 | 12.10 | 0.011 |
B | 65 | 79 | 45.1 | |||
3 yr | A | 102 | 153 | 40.0 | 16.20 | 0.016 |
B | 86 | 58 | 59.7 | |||
Median recurrent bleeding in mo | Four quantile spacing in mo | |||||
Total | A | 10 | (8, 12) | |||
B | 5 | (4, 7) | ≤ 0.001 |
Table 5 Clinical characteristics of the patients in recurrence of ascites
Time | Group | Ascites | Recurrence of ascites, % | χ2 | P value | |||
Yes | No | |||||||
3 mo | A | 15 | 240 | 5.9 | 9.82 | 0.001 | ||
B | 24 | 120 | 16.7 | |||||
6 mo | A | 26 | 229 | 10.2 | 16.15 | 0.005 | ||
B | 35 | 109 | 24.3 | |||||
9 mo | A | 51 | 204 | 20.0 | 12.16 | 0.012 | ||
B | 51 | 93 | 35.4 | |||||
12 mo | A | 87 | 168 | 34.1 | 4.50 | 0.024 | ||
B | 63 | 81 | 43.8 | |||||
2 yr | A | 71 | 184 | 27.8 | 6.56 | 0.018 | ||
B | 57 | 87 | 39.6 | |||||
3 yr | A | 104 | 151 | 40.8 | 10.02 | 0.017 | ||
B | 81 | 63 | 56.3 | |||||
Median recurrent of ascites in mo | Four quantile spacing in mo | |||||||
Total 3 yr | A | 11 | (6, 16) | 0.009 | ||||
B | 16 | (12, 19) |
Table 6 Clinical characteristics of the patients in survival rate and incidence of hepatic encephalopathy
Characteristics | Group | Survival | Survival rate, % | χ2 | P value | |
Yes | No | |||||
1 yr | A | 237 | 18 | 92.9 | 6.98 | 0.008 |
B | 123 | 21 | 85.4 | |||
2 yr | A | 214 | 41 | 83.9 | 14.362 | 0.021 |
B | 98 | 46 | 68.1 | |||
3 yr | A | 177 | 78 | 69.4 | 7.701 | 0.018 |
B | 81 | 63 | 56.3 | |||
HE | Morbidity, % | |||||
Yes | Not | |||||
HE | A | 70 | 185 | 27.5 | 0.40 | 0.527 |
B | 35 | 109 | 24.3 |
- Citation: Dong F, Luo SH, Zheng LJ, Chu JG, Huang H, Zhang XQ, Yao KC. Incidence of portal vein thrombosis after splenectomy and its influence on transjugular intrahepatic portosystemic shunt stent patency. World J Clin Cases 2019; 7(17): 2450-2462
- URL: https://www.wjgnet.com/2307-8960/full/v7/i17/2450.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i17.2450